Ipsen gives back Parkinson’s drug after failing PhIIb study; Paradigm Therapeutics gets global rights to skin treatment
IRLAB Therapeutics has full rights to mesdopetam again after the drug flunked a Phase IIb study involving Parkinson’s patients.
The companies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
